Celsius Holdings to Participate in Upcoming Investor Conferences
Celsius Holdings to Participate in Upcoming Investor Conferences
PR Newswire
BOCA RATON, Fla., March 5, 2024
BOCA RATON, Fla., March 5, 2024 /PRNewswire/ -- Celsius Holdings, Inc., (Nasdaq: CELH), maker of Celsius®, the premium lifestyle energy drink formulated to power active lifestyles with ESSENTIAL ENERGY™, today announced that the company will participate in the following investor conferences:
Stifel Inaugural Consumer Executive Ski Summit 2024
Date: March 7-8, 2024
Bank of America 2024 Consumer & Retail Conference
Date: March 12, 2024
UBS Global Consumer and Retail Conference
Date: March 13-14, 2024
Fireside chat: 2:00 P.M. EDT, March 14, 2024
Fireside chat webcast:
https://event.webcasts.com/viewer/event.jsp?ei=1660525&tp_key=4fd53ebae3
About Celsius Holdings, Inc.
Celsius Holdings, Inc. (Nasdaq: CELH) is the maker of energy drink brand CELSIUS®, a lifestyle energy drink born in fitness and a pioneer in the rapidly growing energy category. For more information, please visit www.celsiusholdings.com.
Investor Relations:
Paul Wiseman
investorrelations@celsius.com
SOURCE Celsius Holdings, Inc.
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track